These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 38413097

  • 1. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).
    Orsini D, Caldarola G, Dattola A, Campione E, Bernardini N, Frascione P, De Simone C, Richetta AG, Galluzzo M, Skroza N, Assorgi C, Amore E, Falco GM, Gaeta Shumak R, Artosi F, Maretti G, Potenza C, Bianchi L, Pellacani G, Peris K, Bonifati C, Graceffa D.
    J Dermatolog Treat; 2024 Dec; 35(1):2319304. PubMed ID: 38413097
    [Abstract] [Full Text] [Related]

  • 2. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L.
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
    Caldarola G, Galluzzo M, Bernardini N, Calabrese L, Grimaldi M, Moretta G, Pagnanelli G, Shumak RG, Talamonti M, Tofani L, Pallotta S, Peris K, Potenza C, De Simone C, Campione E.
    Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).
    Orsini D, Megna M, Assorgi C, Balato A, Balestri R, Bernardini N, Bettacchi A, Bianchelli T, Bianchi L, Buggiani G, Burlando M, Brunasso A, Caldarola G, Cameli N, Campanati A, Campione E, Carugno A, Chersi K, Conti A, Costanzo A, Cozzani E, Cuccia A, D'Amico D, Dal Bello G, Dall'Olio EG, Dapavo P, De Simone C, Di Brizzi EV, Di Cesare A, Dini V, Esposito M, Errichetti E, Fargnoli MC, Fiorella CS, Foti A, Fratton Z, Gaiani FM, Gisondi P, Giuffrida R, Giunta A, Guarneri C, Legori A, Loconsole F, Malagoli P, Narcisi A, Paolinelli M, Potestio L, Prignano F, Rech G, Rossi A, Skroza N, Trovato F, Venturini M, Richetta AG, Pellacani G, Dattola A.
    J Dermatolog Treat; 2024 Dec; 35(1):2393376. PubMed ID: 39164008
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn AM, Kawamura M, Ohtsuki M.
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C.
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, Tada Y, Nemoto O, Rozzo SJ, Kawamura M, Ohtsuki M.
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
    Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN, Burden AD, Smith CH, BADBIR study group and the PSORT consortium.
    Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
    [Abstract] [Full Text] [Related]

  • 17. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
    Melgosa Ramos FJ, Mateu Puchades A, Matáix-Díaz J, Schneller-Pavelescu L, Belinchón-Romero I, Santos Alarcón S.
    Actas Dermosifiliogr; 2024 May; 115(7):722-726. PubMed ID: 38556201
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.